These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17919347)

  • 41. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
    Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
    J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quality indicators for ductal carcinoma in situ (DCIS) of the breast: development using a multidisciplinary delphi process and its use in monitoring population-based treatment.
    Chin-Lenn L; Craighead P; Bryant HE; Mack L; Temple W; Ghali W; Quan ML
    J Surg Oncol; 2013 Nov; 108(6):348-51. PubMed ID: 24038038
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Updates in the treatment of ductal carcinoma in situ of the breast.
    Lebeau A; Kühn T
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):49-58. PubMed ID: 26694830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.
    Lee CW; Wu HK; Lai HW; Wu WP; Chen ST; Chen DR; Chen CJ; Kuo SJ
    Eur J Radiol; 2016 Apr; 85(4):780-9. PubMed ID: 26971424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence map of ductal carcinoma in situ management options.
    Bouskill K; Hempel S; Richardson A; Ganz PA; Baxi S; Zutshi R; Larkin J; Motala A; Miles JNV; Crandall CJ
    Menopause; 2019 Nov; 26(11):1250-1258. PubMed ID: 31567868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The treatment of ductal carcinoma in situ (DCIS) of the breast].
    Westenberg AH; Rutgers EJ; Peterse JL; Hendriks JH; Beex LV; van Tienhoven G
    Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2157-61. PubMed ID: 14626831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy.
    Ravaioli S; Tumedei MM; Foca F; Maltoni R; Rocca A; Massa I; Pietri E; Bravaccini S
    Int J Exp Pathol; 2017 Oct; 98(5):289-295. PubMed ID: 29193395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The treatment of ductal carcinoma in situ of the breast.
    Schwartz GF; Terribile D
    Obstet Gynecol Clin North Am; 2002 Mar; 29(1):189-200, viii-ix. PubMed ID: 11892866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ductal carcinoma in situ of the breast: impact of pathology on therapeutic decisions.
    Jensen RA; Page DL
    Am J Surg Pathol; 2003 Jun; 27(6):828-31. PubMed ID: 12766588
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Rudloff U; Brogi E; Brockway JP; Goldberg JI; Cranor M; Wynveen CA; Nehhozina T; Reiner AS; Patil S; Van Zee KJ
    Cancer; 2009 Mar; 115(6):1203-14. PubMed ID: 19170233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ACR appropriateness criteria(®) ductal carcinoma in situ.
    Moran MS; Bai HX; Harris EE; Arthur DW; Bailey L; Bellon JR; Carey L; Goyal S; Halyard MY; Horst KC; MacDonald SM; Haffty BG;
    Breast J; 2012; 18(1):8-15. PubMed ID: 22107336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan.
    Yotsumoto D; Sagara Y; Kumamaru H; Niikura N; Miyata H; Kanbayashi C; Tsuda H; Yamamoto Y; Aogi K; Kubo M; Tamura K; Hayashi N; Miyashita M; Kadoya T; Saji S; Toi M; Imoto S; Jinno H
    Breast Cancer; 2022 Jan; 29(1):1-8. PubMed ID: 34665435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Who should not undergo breast conservation?
    Nijenhuis MV; Rutgers EJ
    Breast; 2013 Aug; 22 Suppl 2():S110-4. PubMed ID: 24074770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy.
    Noh JM; Lee J; Choi DH; Cho EY; Huh SJ; Park W; Nam SJ; Lee JE; Kil WH
    Breast; 2013 Oct; 22(5):894-7. PubMed ID: 23643805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ductal carcinoma in situ of the breast: our experience.
    Ruggiero R; Procaccini E; Sanguinetti A; Cremone C; Gili S; Docimo G; Docimo L; Sparavigna L; Gubitosi A; Parmeggiani D; Avenia N
    G Chir; 2009 Mar; 30(3):121-4. PubMed ID: 19351465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence.
    Rauch GM; Hobbs BP; Kuerer HM; Scoggins ME; Benveniste AP; Park YM; Caudle AS; Fox PS; Smith BD; Adrada BE; Krishnamurthy S; Yang WT
    Ann Surg Oncol; 2016 Feb; 23(2):482-9. PubMed ID: 26416712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of 23,810 cases of ductal carcinoma-in-situ.
    Sumner WE; Koniaris LG; Snell SE; Spector S; Powell J; Avisar E; Moffat F; Livingstone AS; Franceschi D
    Ann Surg Oncol; 2007 May; 14(5):1638-43. PubMed ID: 17245612
    [TBL] [Abstract][Full Text] [Related]  

  • 59. San Antonio Breast Cancer Symposium explores DCIS "battleground".
    Gottlieb N
    J Natl Cancer Inst; 2000 Feb; 92(4):295-7. PubMed ID: 10675372
    [No Abstract]   [Full Text] [Related]  

  • 60. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.